Compare Stocks: IMTX, GRAL, EWTX, and IOVA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EWTX Edgewise Therapeutics	$44.02 -1.1%	$42.77	$14.25 ▼ $48.51	$4.81B	0.32	1.21 million shs	2.09 million shs
GRAL GRAIL	$109.91 +1.3%	$75.56	$41.50 ▼ $118.84	$4.91B	3.25	945,800 shs	1,075 shs
IMTX Immatics	$8.73 -1.6%	$9.19	$6.90 ▼ $12.41	$1.21B	1.33	474,764 shs	394 shs
IOVA Iovance Biotherapeutics	$10.61 -0.3%	$7.14	$1.76 ▼ $10.98	$4.84B	0.83	15.46 million shs	54,662 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EWTX Edgewise Therapeutics	-0.29%	+2.02%	+0.75%	+5.22%	+194.77%
GRAL GRAIL	+0.51%	+43.00%	+36.43%	+68.01%	+143.97%
IMTX Immatics	+1.72%	+3.14%	-0.67%	-11.48%	+29.49%
IOVA Iovance Biotherapeutics	+4.42%	+13.68%	+28.35%	+150.59%	+401.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EWTX Edgewise Therapeutics	$44.02 -1.1%	$42.77	$14.25 ▼ $48.51	$4.81B	0.32	1.21 million shs	2.09 million shs
GRAL GRAIL	$109.91 +1.3%	$75.56	$41.50 ▼ $118.84	$4.91B	3.25	945,800 shs	1,075 shs
IMTX Immatics	$8.73 -1.6%	$9.19	$6.90 ▼ $12.41	$1.21B	1.33	474,764 shs	394 shs
IOVA Iovance Biotherapeutics	$10.61 -0.3%	$7.14	$1.76 ▼ $10.98	$4.84B	0.83	15.46 million shs	54,662 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EWTX Edgewise Therapeutics	-0.29%	+2.02%	+0.75%	+5.22%	+194.77%
GRAL GRAIL	+0.51%	+43.00%	+36.43%	+68.01%	+143.97%
IMTX Immatics	+1.72%	+3.14%	-0.67%	-11.48%	+29.49%
IOVA Iovance Biotherapeutics	+4.42%	+13.68%	+28.35%	+150.59%	+401.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$51.33	16.61% Upside
GRAL GRAIL	2.33	Hold	$75.10	-31.67% Downside
IMTX Immatics	2.63	Moderate Buy	$20.60	135.97% Upside
IOVA Iovance Biotherapeutics	2.45	Hold	$9.11	-14.14% Downside

Current Analyst Ratings Breakdown

Latest IMTX, GRAL, EWTX, and IOVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	GRAL GRAIL	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$96.00 ➝ $118.00
9/21/2026	EWTX Edgewise Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $57.00
9/18/2026	IMTX Immatics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/17/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$13.00 ➝ $15.00
9/17/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$84.00
9/17/2026	GRAL GRAIL	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform	$84.00
9/17/2026	GRAL GRAIL	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$84.00
9/9/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$105.00
9/9/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$105.00
8/25/2026	IMTX Immatics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$17.00
8/24/2026	IOVA Iovance Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$7.00 ➝ $10.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A
GRAL GRAIL	$147.17M	33.36	N/A	N/A	$66.13 per share	1.66
IMTX Immatics	$54.60M	21.86	N/A	N/A	$4.09 per share	2.13
IOVA Iovance Biotherapeutics	$263.50M	18.24	N/A	N/A	$1.76 per share	6.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)
GRAL GRAIL	-$408.35M	-$9.75	N/A	N/A	N/A	-236.95%	-15.88%	-14.02%	11/11/2026 (Estimated)
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)

Latest IMTX, GRAL, EWTX, and IOVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$99.31 million
8/5/2026	Q2 2026	GRAL GRAIL	-$2.66	-$2.56	+$0.10	-$2.56	$42.39 million	$44.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
GRAL GRAIL	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EWTX Edgewise Therapeutics	N/A	16.24	16.24
GRAL GRAIL	N/A	10.95	10.95
IMTX Immatics	N/A	7.54	7.54
IOVA Iovance Biotherapeutics	N/A	4.34	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EWTX Edgewise Therapeutics	N/A
GRAL GRAIL	N/A
IMTX Immatics	64.41%
IOVA Iovance Biotherapeutics	77.03%

Insider Ownership

Company	Insider Ownership
EWTX Edgewise Therapeutics	21.30%
GRAL GRAIL	1.83%
IMTX Immatics	N/A
IOVA Iovance Biotherapeutics	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EWTX Edgewise Therapeutics	127	108.60 million	85.47 million	Optionable
GRAL GRAIL	910	44.67 million	43.85 million	Optionable
IMTX Immatics	704	136.69 million	N/A	Optionable
IOVA Iovance Biotherapeutics	975	452.97 million	417.64 million	Optionable

IMTX, GRAL, EWTX, and IOVA Headlines

Recent News About These Companies

Iovance Biotherapeutics stock extends rally after strong earnings and cancer therapy momentum

September 22 at 12:54 PM | ad-hoc-news.deA

Is Iovance Biotherapeutics (IOVA) Trading At A Premium To Sales?

September 20 at 1:13 AM | finance.yahoo.com

Why Did Iovance Biotherapeutics (IOVA) Move Today?

September 20 at 1:13 AM | finance.yahoo.com

Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains

September 19, 2026 | marketbeat.com

Iovance Biotherapeutics (IOVA) Receives a Buy from Barclays

September 19, 2026 | theglobeandmail.com

WINTON GROUP Ltd Sells 291,457 Shares of Iovance Biotherapeutics, Inc. $IOVA

September 19, 2026 | marketbeat.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Analysts

September 19, 2026 | americanbankingnews.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Analysts

September 19, 2026 | marketbeat.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

September 18, 2026 | globenewswire.com

4 Biotech Stocks to Watch as Potential Takeover Targets

September 18, 2026 | zacks.com

Investors Purchase Large Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)

September 17, 2026 | marketbeat.com

Iovance Biotherapeutics Sees Unusually Large Options Volume (NASDAQ:IOVA)

September 17, 2026 | marketbeat.com

IOVA stock has gained more than 21% in four sessions, and Barclays sees another 52% upside potential - here’s why

September 17, 2026 | msn.com

Squarepoint Ops LLC Reduces Stock Position in Iovance Biotherapeutics, Inc. $IOVA

September 17, 2026 | marketbeat.com

108,050 Shares in Iovance Biotherapeutics, Inc. $IOVA Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

September 16, 2026 | marketbeat.com

IOVA flags year-end data slate after record Amtagvi quarter, highlights ‘clear line of sight to profitability’

September 15, 2026 | msn.com

Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 1-Year High - Here's Why

September 15, 2026 | americanbankingnews.com

Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 52-Week High - Time to Buy?

September 15, 2026 | marketbeat.com

Financial Survey: ADMA Biologics (NASDAQ:ADMA) versus Iovance Biotherapeutics (NASDAQ:IOVA)

September 15, 2026 | americanbankingnews.com

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 7.8% - What's Next?

September 14, 2026 | marketbeat.com

Wellington Management Group LLP Makes New $531,000 Investment in Iovance Biotherapeutics, Inc. $IOVA

September 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX, GRAL, EWTX, and IOVA Company Descriptions

Edgewise Therapeutics NASDAQ:EWTX

$44.02 -0.49 (-1.10%)

As of 09:37 AM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

GRAIL NASDAQ:GRAL

$109.91 +1.39 (+1.28%)

As of 06:55 AM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Immatics NASDAQ:IMTX

$8.73 -0.14 (-1.58%)

As of 09:37 AM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Iovance Biotherapeutics NASDAQ:IOVA

$10.61 -0.03 (-0.27%)

As of 09:37 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMTX, GRAL, EWTX, and IOVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMTX, GRAL, EWTX, and IOVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMTX, GRAL, EWTX, and IOVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX, GRAL, EWTX, and IOVA Company Descriptions

Edgewise Therapeutics NASDAQ:EWTX

GRAIL NASDAQ:GRAL

Immatics NASDAQ:IMTX

Iovance Biotherapeutics NASDAQ:IOVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMTX, GRAL, EWTX, and IOVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMTX, GRAL, EWTX, and IOVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMTX, GRAL, EWTX, and IOVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX, GRAL, EWTX, and IOVA Company Descriptions

Edgewise Therapeutics NASDAQ:EWTX

GRAIL NASDAQ:GRAL

Immatics NASDAQ:IMTX

Iovance Biotherapeutics NASDAQ:IOVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools